Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Guru Sonpavde MD

Guru P. Sonpavde MD

Medical Director, Genitourinary Oncology; Assistant Director, Clinical Research Unit; Christopher K. Glanz Chair for Bladder Cancer Research, AdventHealth Cancer Institute, Orlando, Florida

Dr. Guru Sonpavde, is the Medical Director of Genitourinary Oncology, Assistant Director of the Clinical Research Unit, and Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute in Orlando, Florida.

With a focus on drug development and translational research in genitourinary cancers, Dr. Sonpavde has led multiple clinical trials studying novel immunotherapy and targeted drugs, particularly for the treatment of bladder cancer. He has also led translational projects and developed prognostic classifications and clinical endpoints focused on bladder cancer. He is a member of Southwest Oncology Group (SWOG) and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Cancers Steering Committee.

Dr. Sonpavde completed his fellowship in medical oncology and hematology at Indiana University.

Disclosures

  • Advisory boards: BMS (Bristol Myers Squibb); Genentech; EMD Serono; Merck; Sanofi; Seattle Genetics/Astellas; AstraZeneca; Exelixis; Janssen; Bicycle Therapeutics; Pfizer; Gilead; Scholar Rock; G1 Therapeutics; Eli Lilly/Loxo Oncology; Infinity Pharmaceuticals; Lucence; IMV Technologies
  • Research funding: Sanofi iAward); AstraZeneca; Gilead; Helsinn; Lucence; Predicine; Bristol Myers Squibb (BMS); EMD Serono; Jazz Therapeutics; GeneCentric; Kure It; NCI (R21)
  • Honoraria:
    • Study steering committees: Unpaid: Bristol Myers Squibb (BMS); Bavarian Nordic; Seattle Genetics; QED, G1 Therapeutics Paid: AstraZeneca; EMD Serono; Debiopharm
    • DSMC: Mereo BioPharma
    • Writing/editing/speaking fees: Wolters Kluwer (UpToDate); Elsevier (PracticeUpdate); Physicians’ Education Resource (PER); OncLive; Research To Practice; Medscape; Cancer Network; Masters Lecture Series (MLS)

Recent Contributions to PracticeUpdate:

  1. Role of Checkpoint Inhibition for Localized Bladder Cancer
  2. Prognostic Model for Patients With Metastatic Urothelial Cancer Receiving Checkpoint Inhibitors
  3. Treatment Sequencing of Checkpoint Inhibitors and Chemotherapy for Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer
  4. Neoadjuvant Chemotherapy Plus Nivolumab and BMS-986205 for Muscle Invasive Bladder Cancer
  5. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma
  6. Variant Histology and Adjuvant Chemotherapy in Bladder Cancer
  7. A New Prognostic Model for Post-Platinum PD-L1 Inhibitors Treatment of Urothelial Carcinoma
  8. Immunotherapy Outcomes in Pure vs Mixed Urothelial Carcinoma Histology
  9. Cost Efficiency and Checkpoint Inhibitors for Urothelial Carcinoma
  10. Chemotherapy for Elderly Patients With Bladder Cancer

Elsewhere

Most Read This Week

Recently Updated